

# Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

## PARP Antibody

RRID:AB\_2160739

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 9542, RRID:AB\_2160739

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2160739](http://antibodyregistry.org/AB_2160739)

**Proper Citation:** Cell Signaling Technology Cat# 9542, RRID:AB\_2160739

**Target Antigen:** PARP

**Host Organism:** rabbit

**Clonality:** polyclonal

**Comments:** Applications: W. Consolidation: AB\_10694650, AB\_2160726, AB\_10831365.

**Antibody Name:** PARP Antibody

**Description:** This polyclonal targets PARP

**Target Organism:** rat, h, m, mouse, r, non-human primate, human, mk

**Antibody ID:** AB\_2160739

**Vendor:** Cell Signaling Technology

**Catalog Number:** 9542

**Alternative Catalog Numbers:** 9542S, 9542P, 9542L

**Record Creation Time:** 20250820T034459+0000

**Record Last Update:** 20250820T170500+0000

---

### Ratings and Alerts

No rating or validation information has been found for PARP Antibody.

No alerts have been found for PARP Antibody.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 323 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Wang J, et al. (2026) Maltol induces diabetic fragility fractures by disrupting the balance of bone remodeling. *Cell metabolism*, 38(6), 1187.

Nguyen TQA, et al. (2026) Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC. *Cell reports. Medicine*, 7(5), 102750.

Xie Y, et al. (2026) QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models. *Molecular cancer therapeutics*, OF1.

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. *Cell reports*, 45(6), 117464.

Cheng P, et al. (2026) PARP1 suppression drives ROS resistance in aneuploid cancer cells. *Molecular cell*, 86(9), 1742.

Sui M, et al. (2026) ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair. *Molecular cancer research : MCR*, 24(1), 7.

Tanka AT, et al. (2026) Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression. *Cancer research*, 86(7), 1586.

Abdrakhmanov A, et al. (2026) A lineage-specific selective autophagy receptor module mediates P-body turnover. *Developmental cell*, 61(4), 744.

Kumariya S, et al. (2026) Transcriptional control of PPP2CB by YAP1 and TEAD1 mediates AMPK inhibition and mTORC1 activation in vascular smooth muscle cells. *iScience*, 29(3), 114996.

Zhao Y, et al. (2026) NAD<sup>+</sup> metabolic collapse and arrest of epithelial development in Hirschsprung disease. *World journal of pediatric surgery*, 9(4), e001222.

Radke K, et al. (2026) Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma. *EMBO molecular medicine*, 18(2), 433.

Thielen N, et al. (2026) High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. *NPJ precision oncology*, 10(1).

Gu Z, et al. (2026) Wntless degradation mediated by CaMKII inhibition drives endoplasmic reticulum stress and apoptosis. *Cell reports*, 45(4), 117256.

Asmanidou S, et al. (2026) BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. *Cell death & disease*, 17(1), 187.

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. *Cell reports. Medicine*, 7(2), 102578.

Doldi V, et al. (2026) FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target. *Journal of translational medicine*, 24(1).

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Asada S, et al. (2026) Disruption of microhomology-mediated end joining in Ewing sarcoma. *Molecular cell*.

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, 84, 101312.

Kim W, et al. (2026) Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. *iScience*, 29(6), 116005.